Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-04

Clinical Trial Update: RAD001(Everolimus) in Treating Patients With Myelodysplastic Syndromes [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating everolimus (RAD001) in patients with myelodysplastic syndromes was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Everolimus (everolimus)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Myelodysplastic Syndromes | Phase 2 | Status: TERMINATED | Results posted: 2012-05-04